The Hormones Upstream of Testosterone: What TRT Actually Does to Pregnenolone, DHEA, and Allopregnanolone

TRT gets discussed almost entirely in terms of one hormone and one number. But testosterone is the downstream output of a longer biochemical chain, and understanding that chain — what feeds into testosterone production, and what branches off in other directions entirely — is what "full hormone optimization" is actually supposed to mean, rather than just a marketing phrase attached to an expanded lab panel. The Cascade, From the Top Every steroid hormone in the body starts from the same raw material: cholesterol. The rate-limiting first step, carried out by an enzyme system involving the StAR protein and CYP11A1, converts cholesterol into pregnenolone — sometimes called the "mother hormone" because every other steroid hormone downstream of it, in every direction, is built from it. From pregnenolone, the pathway branches: one direction leads to DHEA and eventually testosterone, DHT, and estrogen; the other leads to progesterone and, from there, to cortisol on one branch and to a specific neurosteroid, allopregnanolone, on another. This isn't a simple linear ladder — it's closer to a branching tree, and testosterone is just one of several endpoints. How TRT Actually Affects the Upstream Chain — Not Just the Final Output This is the part that gets missed when TRT is framed as simply "adding testosterone." Exogenous testosterone suppresses the pituitary's LH output, and LH is what drives the entire Leydig cell steroidogenic cascade in the testes — not just the final conversion to testosterone, but the very first step of the chain. According to PubMed, a review on TRT and AAS-induced suppression describes how exogenous testosterone administration suppresses gonadotropin (LH and FSH) release from the pituitary, which directly reduces Leydig cell activity and intratesticular hormone production — intratesticular testosterone concentrations run 50-100 times higher than blood levels specifically because of local LH-driven Leydig cell steroidogenesis, and that entire local production system winds down when LH is suppressed ([Desai et al., Therapeutic Advances in Urology, 2022, PMID: 35783920](https://doi.org/10.1177/17562872221105017)). The practical implication: TRT doesn't just add testosterone to the bloodstream — it turns down local testicular production of the whole upstream chain that would otherwise be happening there, including local pregnenolone and DHEA-adjacent intermediates, not exclusively the final testosterone molecule. This is a genuinely important nuance for the "true optimization" framing: a man on TRT isn't just missing his own testosterone production — his testes have also throttled back the broader local steroidogenic activity that was happening upstream of it, which is part of the rationale (covered in our dedicated hCG article) for using hCG specifically to keep that local Leydig cell machinery active rather than fully dormant. Pregnenolone: Real Evidence, But Not for What It's Usually Marketed For As covered in more depth in our hCG and hormone optimization article, pregnenolone has genuine clinical trial evidence — but for a specific, narrower application than most marketing suggests. According to PubMed, a randomized, double-blind, placebo-controlled trial in military veterans with chronic low back pain found pregnenolone produced a clinically meaningful reduction in pain and improved pain-interference scores compared to placebo ([Naylor et al., JAMA Network Open, 2020, PMID: 32119096](https://doi.org/10.1001/jamanetworkopen.2020.0287)). That's real, legitimate trial evidence — for pain, specifically, not for the cognitive-enhancement or general vitality claims often attached to it in supplement marketing. DHEA: Adrenal, Not Just Testicular, and Real Evidence Has Real Limits DHEA (and its sulfated form, DHEA-S) is produced primarily by the adrenal glands, which is an important distinction from testosterone — it isn't nearly as dependent on the same LH-driven testicular pathway TRT suppresses, meaning DHEA decline is more a function of independent, adrenal-related aging than a direct downstream casualty of TRT itself. According to PubMed, a review of age-related DHEA-S decline found real, demonstrated benefit from DHEA replacement specifically in patients with diagnosed adrenal insufficiency, while concluding that normal, healthy age-related decline alone does not clearly justify supplementation in otherwise healthy men, given inconsistent broader metabolic and cardiovascular research ([Perrini et al., Journal of Endocrinological Investigation, 2005, PMID: 16042365](https://pubmed.ncbi.nlm.nih.gov/16042365/)). Allopregnanolone: The Neurosteroid Branch Most TRT Conversations Skip Entirely This is the piece most "full hormone optimization" discussions miss completely, because it isn't an androgen at all — it branches off progesterone, not testosterone, and it has nothing to do with muscle, libido, or the usual TRT conversation. Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of the GABA-A receptor — the same receptor system benzodiazepines act on — and according to PubMed, downregulation of its natural biosynthesis has been directly linked to depression, anxiety, and PTSD, with the mechanism involving GABAergic signaling alongside effects on BDNF, dopamine receptors, and glutamate neurotransmission ([Chen, Gao, Li & Ye, Pharmacological Research, 2021, PMID: 34019980](https://doi.org/10.1016/j.phrs.2021.105682)). This isn't a fringe theoretical claim — the same review notes that a synthetic formulation of allopregnanolone itself (brexanolone) has been FDA-approved specifically for postpartum depression, and a related oral compound (zuranolone) has been developed on the same mechanism. That's about as strong a real-world validation of a neurosteroid pathway as exists in psychiatry. The practical relevance to TRT specifically: allopregnanolone isn't something typically measured or supplemented directly — it's produced from progesterone via specific enzymatic conversion, meaning its availability depends on progesterone status rather than being a separate hormone to add to a protocol. This is worth knowing precisely because it illustrates how incomplete a testosterone-and-estradiol-only panel really is: a man's mood and anxiety regulation may have more to do with this progesterone-derived neurosteroid branch than with anything on a standard TRT lab panel at all. Why Testing Before Supplementing Actually Matters Here This is the throughline across every hormone discussed above, and it's worth stating plainly rather than treating it as boilerplate caution. Pregnenolone, DHEA-S, and the broader upstream cascade all decline with age to some degree, similar to testosterone itself — but as covered throughout this site, "declines with age" and "requires supplementation" are different claims. The pregnenolone trial above showed real benefit specifically for pain in a population that wasn't screened for baseline pregnenolone deficiency; the DHEA-S evidence is genuinely strong only in diagnosed adrenal insufficiency, not normal aging decline. Blindly adding either compound to a TRT protocol without checking actual baseline levels means potentially treating a number that was never actually low, chasing a benefit the trial evidence doesn't support for that specific starting point, or missing a real, correctable deficiency because attention went to testosterone and estradiol alone. The evidence-based approach to "true optimization" isn't adding more compounds to a stack — it's a full panel (pregnenolone, DHEA-S, estradiol, and the thyroid and iron markers covered in our fatigue-focused article) checked before assuming any one piece needs correcting, with supplementation reserved for markers that are actually measured as low, tied to real symptoms, and supported by trial evidence for that specific use case. The Bottom Line Testosterone is one endpoint of a branching hormonal cascade that starts at cholesterol and includes pregnenolone, DHEA, progesterone, and neurosteroids like allopregnanolone that have nothing to do with androgens at all. TRT itself doesn't just add testosterone — by suppressing LH, it turns down the entire local testicular steroidogenic pathway upstream of it, which is part of the real rationale behind hCG use. Pregnenolone and DHEA both have genuine, if narrower-than-marketed, trial evidence behind specific uses, and allopregnanolone represents a validated, FDA-recognized pathway for mood regulation that most TRT conversations never even mention. The actual throughline for anyone pursuing genuine hormone optimization: test the full cascade before supplementing any piece of it, and match supplementation to an actual measured deficiency and a real, evidence-backed indication — not to the assumption that more hormones on the list automatically means a more complete protocol.